NSPR News and Press, InspireMD Inc.

Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board m...

Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...

2024-05-14 10:53:28 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips InspireMD (NASDAQ: NSPR ) just reported results for the first quarter of 2024. InspireMD reported earnings per share of -21 cents. This was below the analyst estimate for ...

2024-05-14 10:50:25 ET InspireMD Inc. (NSPR) Q1 2024 Results Conference Call May 14, 2024 8:30 AM ET Company Participants Chuck Padala - Managing Director Marvin Slosman - President, CEO & Director Craig Shore - CFO, Chief Administrative Officer, Secretary &a...

2024-05-14 07:03:26 ET More on InspireMD InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on InspireMD Historical earnings data for InspireMD Financial information for InspireMD Read the full article on Seek...

- Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced that an abstract detailing one-year outcomes from the C-GUARDIANS IDE clinical trial of CGuard™ Prime has been accepted for presentation at LINC 2...

2024-05-13 12:13:56 ET More on InspireMD InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on InspireMD Historical earnings data for InspireMD Financial information for InspireMD Read the full article on Seek...

TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2024 financial ...

TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentati...

TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of t...